Format

Send to

Choose Destination
J Infect Dis. 2002 Dec 1;186(11):1603-7. Epub 2002 Nov 4.

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.

Author information

1
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. spillai@caregroup.harvard.edu

Abstract

Linezolid is an important therapeutic option for treatment of infections caused by glycopeptide- and beta-lactam-resistant gram-positive organisms. Linezolid resistance is caused by mutations within the domain V region of the 23S ribosomal RNA (rRNA) gene, which is present in multiple copies in most bacteria. Among clinical Staphylococcus aureus isolates, there has been only 1 reported case of linezolid resistance. In the present study, this isolate was further characterized by determination of the number of mutant 23S rRNA copies, assessment of the stability of the resistant phenotype, and comparison of its growth characteristics with those of linezolid-susceptible S. aureus. All 5 copies of the 23S rRNA gene contained a G2576U mutation in the domain V region. After serial passage on antibiotic-free medium, the isolate maintained resistance to high concentrations of linezolid. Compared with 2 linezolid-susceptible S. aureus isolates, the linezolid-resistant S. aureus isolate demonstrated no significant differences in in vitro growth characteristics.

PMID:
12447736
DOI:
10.1086/345368
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center